China-based drug maker TOT Biopharm is developing TAB008 as a biosimilar of the reference bevacizumab, Avastin. TOT has recently indicated that it is in the midst of a phase 3 clinical trial of the biosimilar, and last month, results of a phase 1 study of the biosimilar were published in Frontiers in Pharmacology.
China-based drug maker TOT Biopharm is developing TAB008 as a biosimilar of the reference bevacizumab, Avastin. TOT has recently indicated that it is in the midst of a phase 3 clinical trial of the biosimilar, and the company also raised $102 million last month in series B financing that will, in part, help finance the continued development of the product.
Last month, results of a phase 1 study of the biosimilar were published in Frontiers in Pharmacology after having previously been reported in abstract form at the American Society of Clinical Oncology meeting in 2018, and the study’s authors write that, as well as showing pharmacokinetic (PK) similarity to reference bevacizumab, the biosimilar was safe and well tolerated.
In the randomized, double-blind, parallel controlled study, 100 healthy male volunteers were randomized to receive a single 1-mg/kg dose intravenous dose of either the biosimilar (n = 49, as 1 volunteer experienced an adverse event [AE] not related to the study drug) or the reference bevacizumab (n = 50).
The primary PK parameters were maximum observed concentration (Cmax), the area under the plasma drug concentration—time curve up to time t (AUC0-t), and the area under the plasma drug concentration—time curve to infinite time (AUC0-∞).
The mean concentration profiles between the biosimilar and the reference were similar; the treatment group ratios of the least squares geometric means for the 3 primary PK parameters were fully contained within the prespecified bioequivalence margin of 80.00% to 125.00% (90% CI, 103.66%-118.33% for Cmax; 94.32%-111.72% for AUC0-t; 94.69%-112.23% for AUC0-∞).
Treatment-emergent AEs (TEAEs) were reported in 49.0% of volunteers in the biosimilar group and 44.0% of volunteers in the reference group. TEAEs considered related to bevacizumab were reported in 38.8% of the biosimilar group and 38.0% of the reference group. One volunteer in the biosimilar group and 3 in the reference group experienced grade 3 TEAEs. No TEAEs led to discontinuation.
The most frequently reported AE in both arms was hypertriglyceridemia, and clinically significant hypertension was also observed in both groups. Electrocardiograms and physical examination did not show clinically relevant abnormalities in either group, however.
In terms of immunogenicity, 1 volunteer in the biosimilar group and 1 in the reference group developed new antibodies to bevacizumab. The antidrug antibodies were nonneutralizing.
According to the authors, this study demonstrates that the proposed biosimilar has similar PK to the reference, was safe, and is well tolerated.
Reference
Wang J, Qui L, Liu L, et al. A phase 1, randomized, single-dose study evaluating the biosimilarity of TAB008 to bevacizumab in healthy volunteers. Front Pharmacol. 2019;10:905. doi: 10.3389/fphar.2019.00905.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.